Mental and Cognitive Health Library
Every article, presentation, spotlight, and news item we've tagged to Mental and Cognitive Health.
Showing 73–96 of 203
LRRK2 inhibitor targets neuroinflammation in asymptomatic Alzheimer's risk
Halia Therapeutics demonstrated that HT-4253, a brain-penetrant LRRK2 inhibitor, reduced neuroinflammation, tau phosphorylation, and restored microglial function in preclinical models, with plans to test safety and biomarker effects in cognitively normal APOE4 carriers. This approach targets upstream inflammatory pathways implicated in Alzheimer's pathogenesis before cognitive decline emerges.
Blood Biomarkers Replicate Alzheimer's Brain Imaging Data
DiamiR Biosciences is collaborating with AlzLabs to validate blood-based biomarkers for Alzheimer's disease, measuring phosphorylated tau-217, amyloid ratios, and neurofilament light alongside proprietary microRNA signatures. This work addresses a critical diagnostic gap: replacing expensive, inaccessible PET imaging with accessible blood testing that captures the neurobiological complexity of early-stage disease.
C2N Diagnostics partners with Codex Genetics to expand Alzheimer’s testing in Hong Kong
C2N Diagnostics and Codex Genetics are expanding access to PrecivityAD2, a blood test measuring amyloid biomarkers to assess Alzheimer's risk in asymptomatic or early-symptomatic individuals. Early detection via non-invasive biomarker assessment enables intervention before cognitive decline becomes clinically apparent, shifting Alzheimer's management from reactive to preventive.
From Cultural Bias to Personal Beliefs: Latent Profiles of Ageism and Aging Self-Perceptions. Relationships With Mental Health and Cognitive Outcomes
Ageism and self-perceptions of aging cluster into distinct psychosocial profiles that correlate with cognitive performance and mental health outcomes in older adults. These profiles suggest that internalized attitudes toward aging—shaped by both cultural messaging and personal belief—measurably influence brain function and psychological resilience.
The Effectiveness of an Audiovisual and Game-Based Dementia Educational Program on Healthcare Students’ Attitude: A Pre-post Comparative Study
An audiovisual game-based educational program improved healthcare students' attitudes toward dementia, demonstrating that interactive learning methods can shift perception and potentially influence future clinical care quality. This has indirect relevance to longevity contexts where provider attitudes shape patient outcomes and engagement with cognitive health management.
Microglial transitions control Alzheimer's progression beyond amyloid
Microglial state transitions—shifts in how immune cells in the brain respond to amyloid and tau pathology—emerge as a critical control point in Alzheimer's progression. The research identifies a tipping point where microglia shift from a potentially protective inflammatory state to one associated with neurodegeneration, offering a mechanistic rationale for immune-modulating therapeutic strategies targeting TREM2 signaling.
p75NTR modulation slows Alzheimer's decline 50% in Phase 2
LM11A-31, an oral p75NTR modulator, demonstrated a 50% reduction in cognitive decline progression in mild-to-moderate Alzheimer's disease patients within a Phase 2a trial, with concurrent improvements across multiple brain biomarkers including synaptic connectivity and tau pathology. The finding suggests that targeted neurotropic modulation may preserve functional brain networks in early-stage cognitive decline.
SuperAgers reveal a regenerative brain signature
SuperAgers—individuals over 80 with memory performance matching those decades younger—maintain roughly twice the neurogenic capacity of age-matched peers, driven by preserved epigenetic regulation that keeps regenerative neural programs accessible. This finding reframes cognitive aging from inevitable decline to a regulated, potentially modifiable biological process.
Annovis Bio to discuss multi-protein approach to Alzheimer’s
Annovis Bio is advancing buntanetap, an oral therapy targeting multiple neurotoxic proteins implicated in Alzheimer's disease, moving beyond the single-protein paradigm that has dominated the field. This multi-target approach addresses a fundamental gap between pathophysiological evidence and current therapeutic strategy, with Phase 3 data supporting both clinical benefit and biomarker improvement.
Blood Biomarkers Close Alzheimer's Diagnostic Gap in Latin America
C2N Diagnostics and SouthGenetics are expanding blood-based biomarker testing for Alzheimer's detection across Latin America and the Caribbean, addressing a critical gap between diagnostic innovation and accessibility in underserved regions. This partnership prioritizes implementation over technology alone, recognizing that earlier identification of Alzheimer's pathology becomes actionable only when systems can deploy it at scale.
Non-Pharmacological Sleep Interventions for Dementia Caregivers; A Systematic Review of Randomized Controlled Trials
Dementia caregivers experience chronic sleep disruption that impairs their own health and caregiving capacity. Non-pharmacological interventions—behavioral modifications, cognitive techniques, and environmental adjustments—demonstrate measurable improvements in sleep quality and duration when implemented consistently, with secondary benefits to emotional regulation and stress resilience.
HIV cognitive decline persists despite ART—interventions lack evidence
Cognitive impairment persists in people with HIV despite effective antiretroviral therapy, and evidence for additional interventions to prevent cognitive decline remains limited. This systematic review commissioned by WHO examined pharmacological and non-pharmacological approaches and found insufficient data to establish clear effectiveness, highlighting a significant gap in treatment protocols for HIV-related cognitive decline.
AlzeCure completes Phase Ib study of ACD856
AlzeCure completed Phase Ib evaluation of ACD856, a candidate that modulates BDNF and NGF signaling across the blood-brain barrier. Preclinical evidence suggests neuroprotective and anti-inflammatory effects with potential disease-modifying capacity in cognitive decline and depression.
Provider Burnout Blocks Personalized Geriatric Care
Care providers report significant barriers to delivering person-centered geriatric care, including systemic constraints that undermine their capacity to tailor treatment to individual patient needs and values. Understanding these provider-level obstacles is essential for designing interventions that sustain quality outcomes and prevent clinician burnout in aging populations.
The case for space as a model of accelerated aging
Spaceflight stressors including microgravity and radiation accelerate biological aging pathways in astronauts, providing a compressed model for studying age-related disease mechanisms. This natural experiment offers direct evidence of how extreme environmental conditions trigger aging processes that occur more gradually in terrestrial populations.
Delirium as cognitive marker, not dementia cause
Delirium following severe infection shows strong statistical association with subsequent dementia risk, but the causal mechanism remains unestablished. The timing of dementia diagnoses—predominantly within one year of delirium onset—suggests delirium may unmask existing neurodegenerative processes rather than directly cause cognitive decline.
Supportive Environmental Features at Home as Proactive/Reactive Associates of Disability and Mortality Status in Older Adults
Supportive environmental features in homes—grab bars, accessible layouts, lighting modifications—correlate with reduced disability progression and mortality risk in older adults. Implementation patterns vary significantly, and proactive installation (before functional decline) shows stronger protective associations than reactive modification after disability emerges.
Mining the prodrome of neurodegeneration
Transformer-based analysis of electronic health records identified five distinct subtypes of Alzheimer's and Parkinson's disease, each with unique clinical trajectories, comorbidities, and genetic profiles. This stratification approach enables more precise disease understanding and potentially more targeted intervention strategies across the neurodegenerative disease landscape.
Dementia Care Definitions Fail Global Implementation
Person-centered dementia care remains inconsistently defined across global contexts, with current frameworks biased toward high-income, Western perspectives. An international survey of 39 Alzheimer's associations reveals significant gaps between idealized care principles and implementation across diverse healthcare systems and cultural settings.
MindImmune lands ADDF funding to harness the immune system against Alzheimer’s
MindImmune Therapeutics secured $5 million from the Alzheimer's Drug Discovery Foundation to advance MITI-101, a therapeutic targeting peripheral immune cell migration into the brain rather than amyloid or tau pathology. The approach addresses neuroinflammation as a driver of neurodegeneration, with preclinical evidence showing that blocking CD11c-positive immune cells reduces synaptic deterioration markers.
Dementia eHealth Tools Lack Cultural Fit for Minorities
Digital health interventions for dementia care have proliferated, yet evidence remains sparse on whether these tools are effectively adapted for ethnic minority populations. This scoping review identifies a significant gap: most eHealth interventions target the dementia care triad—patients, informal caregivers, and clinicians—without systematic cultural tailoring or outcome data in diverse communities.
Childhood Adversity and Late-Life Disability
Adverse childhood experiences predict functional disability in older adults through two distinct pathways: increased depressive symptoms and reduced cognitive function. This longitudinal evidence from over a decade of follow-up demonstrates that early-life adversity creates measurable constraints on physical capability decades later, independent of current socioeconomic status.
Sleep barriers in aging: socioeconomic stressors trump age
Sleep disruption in older African American and low-income adults stems from interconnected environmental, social, and physiological stressors rather than aging alone. Understanding these specific barriers—noise, housing instability, health burden, social isolation—is essential for tailoring interventions that address root causes rather than symptoms.
Annovis traces buntanetap’s road to Alzheimer’s
Buntanetap, Annovis Bio's investigational therapy, targets multiple neurotoxic proteins implicated in Alzheimer's and Parkinson's disease rather than a single pathway. This multi-target approach reflects an emerging recognition in longevity science that neurodegeneration involves systemic breakdown across multiple mechanisms, not isolated protein pathology.